Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Briquilimab in Allergic Asthma
NCT06592768Phase 1Terminated
- Sponsor
- Jasper Therapeutics, Inc.
- Start
- Nov 2024
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in allergic asthma comparing Briquilimab with Placebo (2 arms). Primary endpoints: Safety and Tolerability of Briquilimab up to 4.5 months and Late Asthmatic Response at Week 6. Started Nov 2024; status: terminated.
02
Drugs
briquilimab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT06592768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592768.